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mediate recall or total verbal learning.  Conclusion: VDM 
function is influenced by the TCF4 gene in schizophrenia pa-
tients. However, the elevated risk for schizophrenia is not 
conferred by TCF4-mediated VDM impairment. 
 Copyright © 2011 S. Karger AG, Basel
 Introduction 
 Schizophrenia is a severe and disabling disorder which 
belongs to the most burdensome and costly illnesses 
worldwide  [1] . The disorder is characterized by several 
disturbances in affect, cognition and behavior. Family 
studies and twin studies investigating the heritability of 
schizophrenia substantiate a high genetic liability of 
schizophrenia which is estimated to explain up to 85% of 
the variance  [2] . 
 Due to the waning and waxing course of the disorder, 
it has been emphasized to regard the underlying neu-
robiological core features instead of the observable phe-
notype. These intermediate phenotypes, or endophe-
notypes, are assumed to mediate genetic and phenotyp-
ic variation  [3, 4] . Neurocognitive features have proven 
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 Abstract 
 Background: Recently, a role of the transcription factor 4 
(TCF4) gene in schizophrenia has been reported in a large 
genome-wide association study. It has been hypothesized 
that TCF4 affects normal brain development and TCF4 has 
been related to different forms of neurodevelopmental dis-
orders. Schizophrenia patients exhibit strong impairments 
of verbal declarative memory (VDM) functions. Thus, we 
 hypothesized that the disease-associated C allele of the 
rs9960767 polymorphism of the TCF4 gene led to impaired 
VDM functioning in schizophrenia patients.  Method: The 
TCF4 variant was genotyped in 401 schizophrenia patients. 
VDM functioning was measured using the Rey Auditory Ver-
bal Learning Test (RAVLT).  Results: Carriers of the C allele 
were less impaired in recognition compared to those carry-
ing the AA genotype (13.76 vs. 13.06; p = 0.049). Moreover, a 
trend toward higher scores in patients with the risk allele
was found for delayed recall (10.24 vs. 9.41; p = 0.088). The 
TCF4 genotype did not influence intelligence or RAVLT im-
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highly promising endophenotypes in schizophrenia 
 research  [5] . Among others, deficits in verbal declara-
tive memory (VDM) have been investigated extensively, 
yielding standardized effect sizes up to 1.41 (Cohen’s d) 
 [6] . Thus, patients suffering from schizophrenia show 
marked deficits in verbal learning, retrieval and recogni-
tion  [7] . Faraone et al.  [8] demonstrated the cosegregation 
of verbal memory and schizophrenia liability. In their 
analyses, subjects with two or more affected family mem-
bers (multiplex families) showed worse memory func-
tioning than subjects with only one affected family mem-
ber (simplex families) and healthy control subjects. In 
 unaffected relatives, VDM deficits up to d = 0.65 were 
obtained, compared to healthy control subjects  [9–11] . 
 Recently, a large genome-wide association study 
(GWAS) was performed, reporting a novel genetic variant 
conferring a risk for schizophrenia  [12] . This variant is 
located within intron 3 of transcription factor 4 (TCF4). 
The C allele of the rs9960767 polymorphism was found 
to be more frequent in patients with schizophrenia, lead-
ing to a 1.23-fold higher risk for the disorder. The TCF4 
gene is located on chromosome 18q21.2. In their genome 
scan metaanalysis of linkage studies on schizophrenia, 
Lewis et al.  [13] found the 18q21.1-qter ‘bin’ ranked 
around fifteenth in the genome. The TCF4 gene is in-
volved in normal brain development  [14] and has been 
associated with the Pitt-Hopkins syndrome, a severe en-
cephalopathy with autonomic dysfunctions like inter-
mittent hyperventilation  [15–18] . Recently, Kalscheuer et 
al.  [19] reported a de novo translocation disrupting exon 
4 of TCF4 in a girl with mental retardation, thus suggest-
ing that there are also milder phenotypic expressions of 
TCF4 variability compared to the Pitt-Hopkins syn-
drome.
 Since VDM impairments have been related to abnor-
mal hippocampal and prefrontal volume and activation 
in both schizophrenia patients and unaffected relatives 
 [20, 21] , we hypothesized that the TCF4 gene may influ-
ence neurodevelopment and thus alters VDM function-
ing. Following previous results of a recent GWAS, we test-
ed for an association of the risk-conferring C allele of the 
rs9960767 polymorphism with impaired VDM function-
ing in schizophrenia patients.
 Patients and Method 
 Sample 
 For the present investigation, we assessed 401 patients suffer-
ing from schizophrenia. All participants had given their written 
informed consent prior to inclusion. The patients were recruited 
in the Departments of Psychiatry of the Universities of Bonn, Co-
logne, Düsseldorf, Mannheim, Berlin, Tübingen, Jena and Mu-
nich. Diagnoses were established according to criteria of the 
DSM-IV or ICD-10  [22, 23] . Subjects were excluded when diag-
nosed with any neurological disorder. Blood samples were col-
lected and stored in the molecular genetics laboratories at the de-
partments of psychiatry and psychotherapy of the universities of 
Bonn and Munich for genotyping. 
 Measures 
 VDM was assessed by the Rey Auditory Verbal Learning Test 
(RAVLT; German translation: Verbaler Lern- und Merkfähigkeits-
test )  [24] . The RAVLT is a highly reliable and valid test for VDM. 
Subjects are asked to learn a list (list A) of 15 words over 5 trials. 
After that, a second list (list B), consisting of 15 new words which 
have to be learned, is presented. Immediately after this interfer-
ence list and again after 30 min, free recall of list A is assessed 
(delayed recall). Recognition is measured by words read aloud. 
The test person is asked to categorize these words as belonging 
to list A, list B or a new list never presented. The RAVLT provides 
a number of different measures of VDM, all of which generally 
indicate impairments in schizophrenia patients. In order to re-
strict analyses and to reduce the probability of false-positive re-
sults due to   error accumulation, we selected 4 dependent vari-
ables: (1) recalled items from the first learning trial (short-term 
memory); (2) the sum of recalled items over the 5 learning trials 
(total learning); (3) delayed recall after 30 min (delayed recall), 
and (4) the sum of correctly recognized items of list A (recogni-
tion).
 In 198 schizophrenia patients, verbal intelligence was estimat-
ed based on the score in a German vocabulary test, the Mehrfach-
wahl-Wortschatz-Test (MWT-B)  [25] . In the remaining 203 
schizophrenia cases, the German translation of the Wechsler 
Adult Intelligence Scale-Revised (WAIS-R) was used to measure 
intelligence  [26] . 
 Genotyping 
 DNA for single-nucleotide polymorphism (SNP) genotyping 
was isolated from EDTA anticoagulated blood using the Qiagen 
protocol for the Blood & Cell Culture DNA Maxi Kit (Qiagen, 
Hilden, Germany). PCR was performed using 12.5 ng of DNA, the 
Taqman  Universal PCR MasterMix, No AmpErase  UNG and 
Taqman SNP Genotyping Assays for the SNP (all provided by Ap-
plied Biosystems, Foster City, Calif., USA) according to the pro-
tocol for Taqman SNP genotyping (Applied Biosystems). Each as-
say consisted of the unlabeled forward and reverse primers and 
the FAM- and VIC-dye-labeled MGB probes. Those assays are 
designed for allelic discrimination of specific SNP. Both alleles 
were scored in a single well by measuring the fluorescence at the 
end of the PCR, using a Tecan Ultra 384 reader (Tecan, Crailsheim, 
Germany). The excitation and emission wavelengths for the FAM-
labeled probes were 485 and 535 nm, and for the VIC-labeled 
probes, 535 and 590 nm, respectively.
 Statistics 
 All analyses were carried out at a significance level of p = 0.05. 
In order to eliminate center effects, RAVLT data were standard-
ized using z-transformation (mean = 0; SD = 1). Similarly, MWT-
B and WAIS-R data were standardized and Z scores aggregated 
into 1 variable. VDM performance differences were assessed us-
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ing ANOVA with standardized VDM variables as dependent vari-
ables, and genotype or medication status as the independent vari-
able. Pearson correlations were computed to analyze the relation 
between duration of illness and VDM. All analyses were com-
puted using the SPSS package, version 17.0. 
 Results 
 The descriptive characteristics, genotype distribution 
and allele frequencies of the sample are displayed in  ta-
ble 1 . The TCF4 variant was in Hardy-Weinberg equilib-
rium in the present study (p = 0.068). As expected, the 
frequency of the C allele was only 6%. Since the CC geno-
type of the rs9960767 polymorphism was present in only 
4 patients, subjects with either a CA or a CC genotype 
were combined and compared against subjects carrying 
the AA genotype in all subsequent analyses. 
 With regard to the demographic characteristics of the 
sample, no differences were found between TCF4 geno-
types in any of the variables age (F = 0.349; d.f. = 1; p = 
0.555), gender (  2 = 0.027; d.f. = 1; p = 0.870) and intelli-
gence (F = 0.023; d.f. = 1; p = 0.881). The same was true 
for the clinical characteristics of the patient sample: age 
at onset, duration of illness, medication type and DSM-
IV subtype were not related to TCF4 genotype ( table 2 ). 
To analyze the effect of differential drug treatment, we 
compared schizophrenia patients treated with at least 1 
atypical antipsychotic (n = 241) with those being treated 
with only conventional neuroleptics (n = 58). However, 
none of the memory parameters analyzed were affected 
by the type of drug treatment in our study (all p  1 0.20). 
Correlation analyses indicated a small correlation of du-
ration of illness with recognition (r = 0.123; p = 0.016; 
adjusted for age). 
 Next, we analyzed VDM performance as a function of 
the TCF4 genotypes. No significant associations between 
TCF4 genotype and immediate recall (F = 1.25; d.f. = 1;
p = 0.264) and total learning (F = 2.36; d.f. = 1; p = 0.125) 
were found. A trend toward higher performance in CA/
CC genotype carriers in delayed recall emerged (AA ge-
notype: 9.41  8 3.62; CA/CC genotype: 10.24  8 3.27; F = 
2.93; d.f. = 1; p = 0.088) ( fig. 1 ). Moreover, in recognition, 
this genotype was significantly associated with better per-
formance compared to carriers of the AA genotype (AA 
genotype: 13.06  8 2.20; CA/CC genotype: 13.76  8 1.22; 
F = 3.90; d.f. = 1; p = 0.049) ( fig. 1 ). When using age, gen-
der, intelligence and duration of illness as covariates, this 
was a trend finding (AA genotype: 13.09  8 1.08; CA/CC 
genotype: 13.66  8 2.90; F = 2.76; d.f. = 1; p = 0.098), while 
no effect for the remaining memory variables was found.
 Discussion 
 This study investigated the novel schizophrenia can-
didate gene TCF4, which previously was reported to be 
associated with the disorder in a large GWAS  [12] . Based 
on the study conducted by Stefánsson et al.  [12] and on 
the extensive literature documenting highly replicable 
memory deficits in schizophrenia, we had hypothesized 
that schizophrenia subjects carrying the disease-associ-
ated C allele of the variant rs9960767 would show im-
paired verbal memory functioning. Contrary to our a pri-
ori assumption, patients with this allele performed sig-
nificantly better with regard to recognition. Moreover, a 
trend toward a higher mean in recalled words after the 
30-min delay was found in C allele carriers. There was no 
other statistical relationship between VDM deficits and 
TCF4 genotype. 
Table 1. G enotype information and demographic characteristics 
of schizophrenia patients (n = 401)
Age, years 37.8810.9
Gender, % male 58.1
IQ 105.2817.7
CC/CA/AA, n 4/45/352
Allele A frequency 0.934
Allele C frequency 0.066
A ge and IQ are shown as means 8 SD. IQ = Intelligence mea-
sured by MWT-B or WAIS-R.
5.00
6.00
Delayed recall
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 Fig. 1. VDM in schizophrenia patients. Means and SEM of
RAVLT scores are displayed. 
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 The TCF4 gene has been reported to be involved in 
brain development  [14] . Prior studies have shown a role 
of TCF4 in the Pitt-Hopkins syndrome  [15] , a severe neu-
rodevelopmental disorder with serious physiological ab-
normalities  [16–18] . Since a de novo translocation dis-
rupting exon 4 of TCF4 was recently seen in a girl with 
mental retardation, TCF4 is also implicated in milder 
forms of cognitive disabilities compared to the Pitt-Hop-
kins syndrome  [19] . We therefore investigated the poten-
tial role of this gene in neuropsychological dysfunctions 
in schizophrenia. The studies on the Pitt-Hopkins syn-
drome and that conducted by Kalscheuer et al.  [19] , both 
relating the TCF4 gene to mental disabilities, also indi-
cate an influence of TCF4 on general intellectual func-
tioning. However, in our study the TCF4 genotype did 
not affect intelligence in subjects with schizophrenia. Al-
though we had to discard our main hypothesis regarding 
a link between impaired memory functioning and the C 
allele of the rs9960767, the results of the present investi-
gation suggest a role of TCF4 in the development of mem-
ory-related neuronal structures.
 There are several areas of the central nervous system 
involved in memory functioning. Since studies on pa-
tients with lesions of the prefrontal cortex (PFC) and the 
medial-temporal lobe (MTL) found impaired memory
in these patients, numerous studies have investigated the 
role of the PFC and MTL in memory function  [27, 28] . 
Studies linking memory performance with neuronal 
 volume and activation in schizophrenia are in line with 
the findings in healthy subjects. With regard to MTL, a 
well-documented reduction in hippocampus volume in 
schizophrenia patients is evident  [29–31] . These abnor-
mal findings from volumetric studies are further encour-
aged by fMRI studies investigating regional activation 
during memory tasks. Heckers et al.  [32, 33] reported a 
series of studies linking reduced activity in the hippo-
campus and impaired verbal memory function in schizo-
phrenia patients. A recent metaanalysis including 18 im-
aging studies replicated the finding of reduced activation 
of the hippocampus during encoding and retrieval in 
schizophrenia  [20] . The PFC has been related to memory 
deficits in schizophrenia following the observation that 
most schizophrenia patients do not utilize semantic cod-
ing strategies during encoding. In line with this, it has 
been reported that VDM deficits in schizophrenia pa-
tients attenuate after a systematic training in semantic 
coding strategies, or due to a different presentation of the 
material  [34, 35] . In their metaanalysis, Achim and Lep-
age  [20] , among others, found a consistently reduced ac-
tivation of the left inferior PFC in different learning and 
memory tasks in schizophrenia patients compared to 
healthy control subjects. Other studies including those by 
Heckers et al.  [32, 33] mentioned above found elevated 
activity patterns in the PFC during encoding and retriev-
al  [36] . Of particular interest for the present study are in-
vestigations reporting hippocampal data from unaffect-
ed high-risk subjects and relatives of schizophrenics. In 
high-risk subjects, a reduced hippocampal volume has 
been demonstrated  [37] . Seidman et al.  [38] also found 
abnormally reduced hippocampi in unaffected first-de-
gree relatives of schizophrenia patients. Moreover, left 
hippocampal volumes in relatives were positively related 
to VDM deficits found in comparison to healthy control 
subjects  [21] . These results stress a genetically determined 
abnormal hippocampus volume in schizophrenia pa-
tients and their relatives, and thus emphasize a develop-
mental view of the disorder with VDM deficits inherited 
within families. Summing up the evidence on neuronal 
activation and memory in schizophrenia, a well-replicat-
ed insufficiency in the recruitment of the MTL and ab-
Table 2.  Clinical characteristics of schizophrenia patients stratified for genotype
AA CA/CC Statistics
Age at onset, years (n = 385) 25.888.9 24.487.9 t = 0.985; p = 0.325
Duration of illness, years (n = 385) 12.189.6 12.189.9 t = 0.003; p = 0.997
Schizophrenia subtypea, % (n = 394) 74.0:26.0 68.8:31.3 2 = 0.592; p = 0.442
Type of medicationb, % (n = 299) 19.8:80.2 16.2:83.8 2 = 0.273; p = 0.601
A ge and duration of illness are shown as means 8 SD. Different numbers are due to missing data.
a Ratio of paranoid subtype versus other subtypes.
b Ratio of patients treated with only typical antipsychotics versus patients treated with any atypical antipsy-
chotic.
 TCF4 and Memory in Schizophrenia Neuropsychobiology 2011;63:131–136 135
normal activation of the PFC have been reported during 
memory task performance in schizophrenia patients and 
their unaffected relatives. These results prompted us to 
assume a potential link between TCF4 and memory-re-
lated structures which we indirectly tested using VDM 
data from schizophrenia patients. However, we were not 
able to analyze structural hippocampal data in our study. 
Further research should address the relation of TCF4 
variation to hippocampal volume or activation.
 VDM constitutes an excellent endophenotype of 
schizophrenia which has already provided noticeable re-
sults in the search for candidate genes in the last years. 
For instance, the met 66 allele of the brain-derived neuro-
trophic factor 1 gene has been repeatedly associated with 
memory deficits in patients suffering from schizophrenia 
 [39–41] and their unaffected first-degree relatives  [42] . 
Moreover, VDM deficits precede acute psychotic epi-
sodes  [43] and tend to be stable even after antipsychotic 
treatment with second generation neuroleptics  [5] . In our 
study, this was supported by the finding that atypical 
drug treatment was not superior to conventional antipsy-
chotics in terms of memory functioning. The high stabil-
ity of VDM deficits was underlined by the fact that dura-
tion of illness did not show any relation to verbal learning 
or retrieval, while only a small positive correlation of du-
ration of illness with recognition memory was obtained 
in schizophrenia patients. This is in line with a metaanal-
ysis conducted by Aleman et al.  [7] , who did not find any 
relation of duration of illness to memory performance as 
well.
 In conclusion, the elevated risk for developing schizo-
phrenia conferred by the C allele of TCF4 rs9960767 is 
apparently not mediated by VDM deficits. Nevertheless, 
memory functioning is altered by the TCF4 genotype, 
suggesting a role of this variant in the development of 
memory-related brain structures.
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